Sara Espinosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sara Espinosa has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Lingdi Zhang
Department of Biochemistry and Molecular Genetics, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado
4 shared publications- Rui Zhao
University of Colorado Denver
4 shared publications Xueni Li
University of Colorado Denver Anschutz Medical Campus
4 shared publicationsJiansen Jiang
Electron Imaging Center for Nanomachines, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA
2 shared publicationsKirk C. Hansen
Department of Biochemistry and Molecular Genetics, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 80045, USA
2 shared publicationsRyan C. Hill
Department of Biochemistry and Molecular Genetics, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 80045, USA
2 shared publications
Latest Publications
- Open Access
- 31 October 2022
- Published by Cold Spring Harbor Laboratory in RNA
- Vol. 29 (1) , 97-110
Human PRPF39 is an alternative splicing factor recruiting U1 snRNP to weak 5′ splice sites
Human PRPF39 is a homolog of the yeast Prp39 and Prp42 paralogs. We have previously shown that human PRPF39 forms a homodimer that interacts with the CTD of U1C, mirroring the yeast Prp39/Prp42 heterodimer. We demonstrate here that PRPF39 knockdown in HEK293 cells affects many alternative splicing events primarily by reducing the usage of weak 5′ ss. Additionally, PRPF39 preferentially binds to a GC-rich RNA, likely at the interface between its NTD and CTD. These data indicate that PRPF39 potentially recruits U1 snRNP to a weak 5′ ss, serving as a previously unrecognized alternative splicing factor. We further demonstrate that human TIA1 binds to U1C through its RRM1 and RRM3 + Q domains and has weak binding to PRPF39. Finally, all three human LUC7L isoforms directly interact with U1C and with PRPF39. These results reveal significant parallels to the yeast U1 snRNP structure and support the use of yeast U1 snRNP as a model for understanding the mechanism of human alternative splicing.
- 31 October 2022
- Published by Cold Spring Harbor Laboratory in RNA
- Vol. 29 (1) , 97-110
Open AccessHuman PRPF39 is an alternative splicing factor recruiting U1 snRNP to weak 5′ splice sites
Human PRPF39 is a homolog of the yeast Prp39 and Prp42 paralogs. We have previously shown that human PRPF39 forms a homodimer that interacts with the CTD of U1C, mirroring the yeast Prp39/Prp42 heterodimer. We demonstrate here that PRPF39 knockdown in HEK293 cells affects many alternative splicing events primarily by reducing the usage of weak 5′ ss. Additionally, PRPF39 preferentially binds to a GC-rich RNA, likely at the interface between its NTD and CTD. These data indicate that PRPF39 potentially recruits U1 snRNP to a weak 5′ ss, serving as a previously unrecognized alternative splicing factor. We further demonstrate that human TIA1 binds to U1C through its RRM1 and RRM3 + Q domains and has weak binding to PRPF39. Finally, all three human LUC7L isoforms directly interact with U1C and with PRPF39. These results reveal significant parallels to the yeast U1 snRNP structure and support the use of yeast U1 snRNP as a model for understanding the mechanism of human alternative splicing.
RNAs in the spliceosome: Insight from cryoEM structures
Pre‐mRNA splicing is catalyzed by the spliceosome, a multimegadalton RNA–protein complex. The spliceosome undergoes dramatic compositional and conformational changes through the splicing cycle, forming at least 10 distinct complexes. Recent high‐resolution cryoEM structures of various spliceosomal complexes revealed unprecedented details of this large molecular machine. This review highlights insight into the structure and function of the spliceosomal RNA components obtained from these new structures, with a focus on the yeast spliceosome.This article is categorized under: RNA Processing > Splicing Mechanisms RNA Structure and Dynamics > RNA Structure, Dynamics, and Chemistry RNA Interactions with Proteins and Other Molecules > RNA–Protein Complexes
RNAs in the spliceosome: Insight from cryoEM structures
Pre‐mRNA splicing is catalyzed by the spliceosome, a multimegadalton RNA–protein complex. The spliceosome undergoes dramatic compositional and conformational changes through the splicing cycle, forming at least 10 distinct complexes. Recent high‐resolution cryoEM structures of various spliceosomal complexes revealed unprecedented details of this large molecular machine. This review highlights insight into the structure and function of the spliceosomal RNA components obtained from these new structures, with a focus on the yeast spliceosome.This article is categorized under: RNA Processing > Splicing Mechanisms RNA Structure and Dynamics > RNA Structure, Dynamics, and Chemistry RNA Interactions with Proteins and Other Molecules > RNA–Protein Complexes
- Open Access
- 11 April 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1495
Author Correction: CryoEM structure of Saccharomyces cerevisiae U1 snRNP offers insight into alternative splicing
The originally published version of this Article contained several errors in Figure 2, panel a: the basepair register in SL3-4 of yeast U1 snRNA was depicted incorrectly; the basepair for A287-U295 in yeast U1 snRNA was erroneously present; basepairs for U84-G119, G309-U532, A288-U295 and U289-A294 in yeast U1 snRNA were missing; the bulging nucleotide in SL3 of human U1 snRNA was depicted as G instead of C; and the dashed boxes defining the 5′ ss binding site and Sm site in both human and yeast snRNAs were not drawn accurately. These have now been corrected in both the PDF and HTML versions of the Article.
- 11 April 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1495
Open AccessAuthor Correction: CryoEM structure of Saccharomyces cerevisiae U1 snRNP offers insight into alternative splicing
The originally published version of this Article contained several errors in Figure 2, panel a: the basepair register in SL3-4 of yeast U1 snRNA was depicted incorrectly; the basepair for A287-U295 in yeast U1 snRNA was erroneously present; basepairs for U84-G119, G309-U532, A288-U295 and U289-A294 in yeast U1 snRNA were missing; the bulging nucleotide in SL3 of human U1 snRNA was depicted as G instead of C; and the dashed boxes defining the 5′ ss binding site and Sm site in both human and yeast snRNAs were not drawn accurately. These have now been corrected in both the PDF and HTML versions of the Article.
- Open Access
- 19 October 2017
- Published by Springer Nature in Nature Communications
- Vol. 8 (1) , 1035
CryoEM structure of Saccharomyces cerevisiae U1 snRNP offers insight into alternative splicing
U1 snRNP plays a critical role in 5ʹ-splice site recognition and is a frequent target of alternative splicing factors. These factors transiently associate with human U1 snRNP and are not amenable for structural studies, while their Saccharomyces cerevisiae (yeast) homologs are stable components of U1 snRNP. Here, we report the cryoEM structure of yeast U1 snRNP at 3.6 Å resolution with atomic models for ten core proteins, nearly all essential domains of its RNA, and five stably associated auxiliary proteins. The foot-shaped yeast U1 snRNP contains a core in the “ball-and-toes” region architecturally similar to the human U1 snRNP. All auxiliary proteins are in the “arch-and-heel” region and connected to the core through the Prp42/Prp39 paralogs. Our demonstration that homodimeric human PrpF39 directly interacts with U1C-CTD, mirroring yeast Prp42/Prp39, supports yeast U1 snRNP as a model for understanding how transiently associated auxiliary proteins recruit human U1 snRNP in alternative splicing.
- 19 October 2017
- Published by Springer Nature in Nature Communications
- Vol. 8 (1) , 1035
Open AccessCryoEM structure of Saccharomyces cerevisiae U1 snRNP offers insight into alternative splicing
U1 snRNP plays a critical role in 5ʹ-splice site recognition and is a frequent target of alternative splicing factors. These factors transiently associate with human U1 snRNP and are not amenable for structural studies, while their Saccharomyces cerevisiae (yeast) homologs are stable components of U1 snRNP. Here, we report the cryoEM structure of yeast U1 snRNP at 3.6 Å resolution with atomic models for ten core proteins, nearly all essential domains of its RNA, and five stably associated auxiliary proteins. The foot-shaped yeast U1 snRNP contains a core in the “ball-and-toes” region architecturally similar to the human U1 snRNP. All auxiliary proteins are in the “arch-and-heel” region and connected to the core through the Prp42/Prp39 paralogs. Our demonstration that homodimeric human PrpF39 directly interacts with U1C-CTD, mirroring yeast Prp42/Prp39, supports yeast U1 snRNP as a model for understanding how transiently associated auxiliary proteins recruit human U1 snRNP in alternative splicing.
- 13 March 2007
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 57 (4) , 243-249
Anti‐tumor and Anti‐ovarian Autoantibodies in Women with Ovarian Cancer
Problem: There is a lack of validated marker(s) for the diagnosis of early‐stage ovarian cancer (OVCA). The objective was to determine if women with OVCA had antibodies, to assess their potential as markers of ovarian cancer. The secondary objective was to compare the prevalence of antibodies to proteins from normal ovary and ovarian tumors to determine if antibodies primarily recognize tumor antigens, as many antigens are common to tumor and normal ovary.Method of Study: Serum samples from patients with OVCA, borderline or benign ovarian tumors, endometrial cancer and healthy women were examined for anti‐ovarian and anti‐tumor antibodies by immunoassay. Immunoreactive proteins were characterized by one‐ and two‐dimensional Western blot.Results: Ovarian (81%, P 0.001) and anti‐tumor (69%, P 0.001) autoantibodies in OVCA were significantly different from those of control sera. A majority of OVCA serum samples reacted with proteins at about 50 kDa from normal ovary or ovarian tumors in one‐dimensional Western blot. While there were similar reactions in two‐dimensional Western blots, there are differences between reactions to normal and tumor antigens and between reactions to autologous and allogeneic tumors.Conclusion: Serum autoantibodies are significantly associated with OVCA. Anti‐tumor antibodies may provide a useful marker for the detection of ovarian cancer.
- 13 March 2007
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 57 (4) , 243-249
Anti‐tumor and Anti‐ovarian Autoantibodies in Women with Ovarian Cancer
Problem: There is a lack of validated marker(s) for the diagnosis of early‐stage ovarian cancer (OVCA). The objective was to determine if women with OVCA had antibodies, to assess their potential as markers of ovarian cancer. The secondary objective was to compare the prevalence of antibodies to proteins from normal ovary and ovarian tumors to determine if antibodies primarily recognize tumor antigens, as many antigens are common to tumor and normal ovary.Method of Study: Serum samples from patients with OVCA, borderline or benign ovarian tumors, endometrial cancer and healthy women were examined for anti‐ovarian and anti‐tumor antibodies by immunoassay. Immunoreactive proteins were characterized by one‐ and two‐dimensional Western blot.Results: Ovarian (81%, P 0.001) and anti‐tumor (69%, P 0.001) autoantibodies in OVCA were significantly different from those of control sera. A majority of OVCA serum samples reacted with proteins at about 50 kDa from normal ovary or ovarian tumors in one‐dimensional Western blot. While there were similar reactions in two‐dimensional Western blots, there are differences between reactions to normal and tumor antigens and between reactions to autologous and allogeneic tumors.Conclusion: Serum autoantibodies are significantly associated with OVCA. Anti‐tumor antibodies may provide a useful marker for the detection of ovarian cancer.